On August 31, 2026 Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, reported that the Company will present data from the ENABLE Phase 1 clinical trial of ELVN-001 in an oral and a poster presentation at the Society of Hematologic Oncology (SOHO) Annual Meeting, taking place September 9-12, 2026, at the George R. Brown Convention Center in Houston, Texas. This is an encore presentation of data that were previously presented at the European Hematology Association (EHA) (Free EHA Whitepaper) 2026 Congress.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the presentation are as follows:
Title: ENABLE: A Phase 1 Study of ELVN-001, a Novel, Selective ATP-Competitive Inhibitor of BCR::ABL1, in Patients with Previously Treated CP-CML
Presenter: Fadi Haddad, M.D.
Poster Session: Wednesday, September 9, 6:55-7:55 p.m. CDT
Poster Location: Hall B3, Level 3
Poster Number: CML-652
Oral Session Title: Session V: Chronic Myeloid Leukemia
Oral Session Date/Time: Thursday, September 10, 11:47 – 11:57 a.m. CDT
Following the presentation, a copy will be available on the "Program Presentations & Publications" section of the Company’s website at www.enliventherapeutics.com.
About the ENABLE Trial
The ENABLE study (NCT05304377) is a Phase 1 study of ELVN-001 in patients with previously treated CML. ENABLE is a dose escalation and expansion trial designed to evaluate safety and tolerability and to determine the recommended dose for further clinical evaluation of ELVN-001 in patients with CML with and without T315I mutations that is relapsed, refractory or intolerant to tyrosine kinase inhibitors (TKIs). Secondary endpoints include pharmacokinetics, major molecular response (MMR) by central quantitative reverse transcriptase polymerase chain reaction, duration of MMR, BCR::ABL1 transcript levels and complete hematologic response.
About ELVN-001
ELVN-001 is a potent, highly selective, potentially best-in-class small molecule kinase inhibitor designed to specifically target the BCR::ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. As a highly selective active-site TKI, ELVN-001 has a mechanism of action that is complementary to allosteric BCR::ABL1 inhibitors, which may play an increasingly important role in the standard of care. ELVN-001 was also designed to have activity against the T315I mutation, the most common BCR::ABL1 mutation, which confers resistance to nearly all approved TKIs, as well as activity against mutations known to confer resistance to allosteric BCR::ABL1 inhibitors.
(Press release, Enliven Therapeutics, AUG 31, 2026, View Source [SID1234670458])